Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs ORM 12741 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NEBULA
- Sponsors Orion
- 28 Jul 2017 Planned primary completion date changed from 30 Nov 2017 to 30 Oct 2017.
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Apr 2017 Planned End Date changed from 1 Jul 2017 to 30 Dec 2017.